You are here

Article Text

Article menu

Download PDFPDF

Section 3: Production and compounding
3PC-039 Early de-risking of the stability of a personalised, sterile bacteriophage suspension on the basis of advanced kinetic modelling
Free
  1. C Merienne1,2,
  2. B Lapras1,2,3,
  3. C Marchand1,2,
  4. M Medina2,4,5,
  5. T Briot2,6,
  6. C Paillet1,2,
  7. F Laurent2,5,
  8. F Pirot1,2,3
  1. 1Fripharm®, Pharmacie À Usage Intérieur- Groupement Hospitalier Centre – Hospices Civils de Lyon Hcl- France, Lyon, France
  2. 2Consortium Phag-One, Hospices Civils de Lyon, Lyon, France
  3. 3UMR 5305: Laboratoire de Biologie Tissulaire et d’ingénierie Thérapeutique, Institut de Biologie et Chimie des Protéines- Cnrs/Université Claude Bernard Lyon 1, Lyon, France
  4. 4Laboratoire de Bactériologie, Institut des Agents Infectieux- Centre National de Référence des Staphylocoques – Hcl, Lyon, France
  5. 5Centre International de Recherche en Infectiologie, Inserm U1111- Université Claude Bernard Lyon 1- France, Lyon, France
  6. 6Pharmacie À Usage Intérieur- Groupement Hospitalier Nord, Hoscipes Civils de Lyon, Lyon, France

Abstract

Background and Importance Bacteriophages, natural viruses of bacteria, are a promising therapy against multidrug-resistant bacteria. The use of therapeutic bacteriophages (TBP) requires the selection of the most active ones and their individual formulations (hospital or magistral preparations) by a hospital pharmacy for a personalised medicine. The risk of TBP instability must be managed at the earliest stages of development.

Aim and Objectives Advanced Kinetic Modelling reliability assessment to de-risk the instability of BPT formulations.

Material and Methods A purified anti-staphylococcal BP (Silviavirus) formulated in two solutions (A and B) was tested. The main critical quality attribute to assess their stability was the biological activity, determined by numeration of Plaque Forming Unit (PFU) (Spot Test), with a target set at (10 ± 9).108 PFU/mL. The following study designs were performed: (i) an accelerated degradation with seven temperature conditions (from -80 °C to +50 °C) during 3 months (analysis at D0, D7, D14, D28, D60, and D90), the data generated being used for AKM with PREDISTAB method; (ii) a prospective stability study based on spot test performed (n=3) at 5 and 25 °C during 12 months for A and 6 months for B.

Results The results (expressed in PFU/mL) of the prospective vs predicted stability studies were as follows:

  • for solution A

  • 8 vs 2.43x108 (DLOG=0.66%) and 1.04x105 vs 2.65x105 (DLOG=8.1%)

  • 8 vs 1.46 x108 (DLOG=2.05%) and 3.56x102 vs 4.76x102 (DLOG=4.94%)

  • for solution B at 5° and 25°C after 6 months: 2.56x108 vs 5.60x108 (DLOG=4.04%) and 1.67x104 vs 2.69x103(DLOG=18.78%)

Conclusion and Relevance Our data suggest that AKM allows rapid assessment of the risk of instability for both formulations. Comparison of the results of the predictive vs prospective stability studies showed a good precision at 5 °C and 25 °C during 12 months for formulation A and 6 months for formulation B. The prospective study is still ongoing for both formulations to be compared with predictions at 24 months. The PREDISTAB method by identifying the risk of instability at the earliest stage of development should allow the early selection of the best TBP formulation and predict the expiry date.

Conflict of Interest No conflict of interest.

https://doi.org/10.1136/ejhpharm-2024-eahp.96

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.